Potential for biosimilars in rheumatology in Africa.

Mohamed Hassan Abu-Zaid, Adewale Adebajo, Yasser El Miedany

Annals of the rheumatic diseases 2023 Dec

filter terms:

Biosimilars are products which are highly similar to a reference biologic product (RBP). In Africa, regulatory frameworks for biosimilar approval are still in development in many countries and few biosimilars for rheumatic diseases are currently available. The use of biosimilar medicines in Africa provides an important opportunity to treat more rheumatology patients with biologic drugs. This editorial aims to shed a light on the potential benefits, challenges and current efforts, regarding the use of biosimilars in Africa in Rheumatology. © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Citation

Mohamed Hassan Abu-Zaid, Adewale Adebajo, Yasser El Miedany. Potential for biosimilars in rheumatology in Africa. Annals of the rheumatic diseases. 2023 Dec;82(12):1508-1510